6/12/2025

Janusmed kön och genus

Janusmed kön och genus – Entyvio

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Vedolizumab

Vedolizumab

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Forss A, Clements M, Bergman D, Roelstraete B, Kaplan GG, Myrelid P et al. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther. 2022;55(6):691-699.

  2. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42(2):188-202.

  3. Chhibba T, Wong ECL, Reinisch W, Targownik L, Narula N. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. Eur J Gastroenterol Hepatol. 2024;36(6):704-711.

  4. Entyvio (vedolizumab). Summary of Product Characteristics. European Medicines Agency [updated 2018-12-12, cited 2025-04-28]

  5. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.

  6. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022;16(1):27-38.

  7. Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572e12.

  8. Azzam N, Alharbi O, Altuwaijri M, Alruthia Y, Alfarhan H, Alshankiti S et al. The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group. Saudi J Gastroenterol. 2025;31(1):34-40.

  9. Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis. 2020;35(8):1489-1500.

  10. Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2020;14(5):694-709.

  11. Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722-729.

  12. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-851.

  13. Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C et al. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients. Dig Dis Sci. 2023;68(5):1983-1994.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Forss A, Clements M, Bergman D, Roelstraete B, Kaplan GG, Myrelid P et al. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther. 2022;55(6):691-699.
  2. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42(2):188-202.
  3. Chhibba T, Wong ECL, Reinisch W, Targownik L, Narula N. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. Eur J Gastroenterol Hepatol. 2024;36(6):704-711.
  4. Entyvio (vedolizumab). Summary of Product Characteristics. European Medicines Agency [updated 2018-12-12, cited 2025-04-28]
  5. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
  6. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022;16(1):27-38.
  7. Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572e12.
  8. Azzam N, Alharbi O, Altuwaijri M, Alruthia Y, Alfarhan H, Alshankiti S et al. The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group. Saudi J Gastroenterol. 2025;31(1):34-40.
  9. Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis. 2020;35(8):1489-1500.
  10. Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2020;14(5):694-709.
  11. Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722-729.
  12. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-851.
  13. Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C et al. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients. Dig Dis Sci. 2023;68(5):1983-1994.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]